TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)

MINUTES OF THE 1ST EXTRAORDINARY GENERAL MEETING OF TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED (THE "COMPANY") FOR FY2026 HELD ON 31 JULY 2026

DATE	:	31 July 2026
TIME	:	2:00 p.m.
VENUE	:	Meeting room of Da Ren Tang Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the People's Republic of China ("**PRC**") 300193 for holders of "A" shares ("**A-Share Shareholders**") Concurrently, via video conferencing at 171 Chin Swee Road, CES Centre, Level 2, #02-14, Singapore 169877 for holders of the "S" shares in Singapore ("**S-Share Shareholders**", together with A-Share Shareholders, "**Shareholders**")
CALLED BY	:	Board of Directors
CHAIRMAN OF THE EGM	:	Ms. Wang Lei

INTRODUCTION

The Chairman of the EGM ("**EGM Chairman**") welcomed all Shareholders to the Company's 1st extraordinary general meeting for the financial year ending 31 December 2026 ("**FY2026**") ("**EGM**" or "**Extraordinary General Meeting**") and stated that the EGM was held at the meeting room of Da Ren Tang Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the PRC, and concurrently, via video conferencing at 171 Chin Swee Road, CES Centre, Level 2, #02-14, Singapore 169877 for the S-Share Shareholders in Singapore. The EGM Chairman stated that voting by the A-Share Shareholders at the EGM is to be carried out through a combination of on-site voting and online voting and then called for the proceedings of the EGM to officially start.

QUORUM

As a quorum was present, Ms. Wang Lei, the EGM Chairman, called the EGM to order at 2:00 p.m.

Ms. Wang Lei, the EGM Chairman, then introduced the following persons who were present at the EGM:

Tianjin:

Directors	-	Ms. Wang Lei (Chairman of the Board) Ms. Zhai Shuping (Independent and Non-Executive Director)

		Mr. Guo Min (Executive Director) Mr. Shang Mingjie (Executive Director) Mr. Zhou Hong (Executive Director)
Secretary to the Board	-	Ms. Jiao Yan
Management	-	Mr. Chen Hong (Executive Deputy General Manager) Mr. Ma Jian (Chief Financial Officer) Mr. Zhou Hong (Deputy General Manager and Chief Engineer)
PRC Legal Counsel	-	Guantao Law Firm (Tianjin Office) Represented by: Mr. Xu Tao Ms. Liu Ying

Singapore:

Singapore Legal Counsel	-	Shook Lin & Bok LLP Represented by: Ms. Nicole Zheng Ms. Caren Ikawan
Singapore Polling Agent	-	Boardroom Corporate & Advisory Services Pte. Ltd. Represented by: Mr. Chan Kok Leong Ms. Loke Li Yean Mr. Chai Min Fung Ms. Loo Zhi Ying
Singapore Scrutineer	-	DrewCorp Services Pte. Ltd. Represented by: Ms. Cheah Xiao Chien Mr. Yeong Xu Hong

NOTICE OF MEETING AND BUSINESS OF THE EGM

Ms. Wang Lei, the EGM Chairman, stated that the meeting materials had been sent to Shareholders and/or published on the website of the Shanghai Stock Exchange and via SGXNet, and the notice convening the EGM was taken as read. The EGM proceeded to consider the resolutions tabled for Shareholders' approval at the EGM.

Ms. Wang Lei, the EGM Chairman, on behalf of the directors and management of the Company, proceeded to address substantial and relevant questions relating to the resolutions tabled at the EGM. The Company did not receive any substantial and relevant questions from the S-Share Shareholder(s) prior to the EGM. The substantial and relevant questions raised by Shareholders at the EGM, and the Company's responses thereto, are set out in **Appendix 1** to this announcement.

VOTING PROCEEDINGS AND RESULTS

Ms. Wang Lei, the EGM Chairman, stated that with respect to voting by the A-Share Shareholders, the scrutineer team comprised Mr. Xu Tao (representative of the PRC legal counsel), Mr. Ren Donghui and Mr. Yang Yang (representatives of the A-Share Shareholders), and the counting personnel comprised Ms. Jiang Ling and Ms. Ma Jingfen. It was noted that Drewcorp Services Pte. Ltd. was appointed as the Singapore scrutineer for the EGM.

Mr. Xu Tao introduced the voting rules and procedures for the A-Share Shareholders on behalf of the scrutineer team, and the Singapore Polling Agent introduced the voting rules and procedures for the S-Share Shareholders. Following this, Shareholders proceeded to vote, and the EGM was adjourned for approximately 1.5 hours.

The EGM resumed at 4:00 p.m., and Ms. Jiao Yan, on behalf of the EGM Chairman, proceeded to announce the voting results for each resolution.

Resolution 1 - To consider and approve the proposed adoption of the remuneration policy for directors and senior management (《董事、高级管理人员薪酬管理制度》)

FOR		AGAINST		FORFEITED	
Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
333,047,091	99.862	173,700	0.052	287,100	0.086

Based on the voting results, Ms. Jiao Yan, on behalf of the EGM Chairman, declared the motion carried.

Resolution 2 - To consider and approve the directors' remuneration proposal for 2026 (《2026年度董事薪酬方案》)

FOR		AGAINST		FORFEITED	
Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
333,042,891	99.861	180,000	0.054	285,000	0.085

Based on the voting results, Ms. Jiao Yan, on behalf of the EGM Chairman, declared the motion carried.

The following director of the Company abstained from voting on Resolution 2:

Name	Number of shares held[1]
Zhou Hong	23,800 Restricted A-shares

WITNESSED BY PRC LEGAL COUNSEL

Mr. Xu Tao, the representative of the PRC legal counsel of the Company, confirmed that the calling and convening of the EGM were in compliance with provisions of relevant laws, regulations and normative documents. The eligibility of the Board of Directors to call the EGM and the presence of the Shareholders at the EGM were legitimate and valid. The voting procedures and results of the EGM were legitimate and valid.

CLOSURE

There being no other business to transact, Ms. Wang Lei, the EGM Chairman, declared the EGM of the Company closed at 4:05 p.m. and thanked everyone for their attendance.

CONFIRMED AS A TRUE RECORD OF PROCEEDINGS HELD

Ms. Wang Lei
Chairman of the Board

[1] These are the Restricted A-Shares (as defined under the Scheme) granted and issued under the 2019 Restricted A-Share Incentive Scheme (2019 年 A 股限制性股票计划) (the "**Scheme**") of the Company.

APPENDIX 1
QUESTIONS FROM SHAREHOLDERS AND COMPANY'S RESPONSES

*All capitalised terms used in this Appendix 1 which are not defined herein shall have the same meanings ascribed to them in the Company's circular dated 16 July 2026 (the "**Circular**").*

Question 1

How will Resolution 1 relating to the Proposed Adoption of the Remuneration Policy benefit Shareholders? How will the Remuneration Policy be implemented, and what changes have been made?

Company's Response

The Company explained that, as stated in Section 2.1 of the Circular, pursuant to the PRC CG Code and the related implementation requirements issued by the CSRC, PRC-listed companies are required to formulate, or, where applicable, review and enhance, their remuneration management policies for directors and senior management. The Remuneration Policy is intended to enhance the Company's management standards, establish an effective incentive and accountability framework, promote internal equity and external competitiveness in its remuneration arrangements, and strengthen the Company's market competitiveness and capacity for sustainable development.

The Remuneration Policy has been formulated taking into account the relevant requirements of the PRC CG Code and the Company's particular business and operational circumstances. As summarised in Section 2.2 of the Circular and set out in full in Appendix A thereto, the Remuneration Policy provides for, among other things, the remuneration structure for Directors and Senior Management, performance assessment and duty evaluation, remuneration administration and adjustment, as well as malus and clawback arrangements. The Company is required by the CSRC to complete the formulation of the Remuneration Policy and obtain the requisite Shareholders' approval by 31 July 2026.

Question 2

If there is a change in the Company's substantial shareholders, how would this affect other Shareholders and the remuneration of the Directors?

Company's Response

The Company clarified that any change in the Company's substantial shareholders would have no direct bearing on the Remuneration Policy.

Question 3

How does the Company assess the performance of key products under its "second growth curve" strategy (战略第二曲线的大单品)?

Company's Response

The Company explained that it has established a comprehensive and structured KPI assessment framework covering its pharmaceutical product tiers, Greater Health products and individual store-opening projects, with assessments extending to individual products (including products outside the designated product tiers). The relative importance of tiered products, strategic products and strategic business segments is reflected through the weighting assigned to the relevant KPIs.